FTO promotes proliferation and migration of bladder cancer via enhancing stability of STAT3 mRNA in an m6A-dependent manner

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA A Cancer J Clin. 2021;71(3):209–12. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology. 2006;49(3):466–5. doi: 10.1016/j.eururo.2005.12.031 discussion 475-7.
   PubMed Web of Science ®Google Scholar
• Roignant JY, Soller M. M(6)a in mRNA: an ancient mechanism for fine-tuning gene expression. Trends Genet. 2017;33(6):380–390. doi: 10.1016/j.tig.2017.04.003
   PubMed Web of Science ®Google Scholar
• Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71(10):3971–3975. doi: 10.1073/pnas.71.10.3971
   PubMed Web of Science ®Google Scholar
• He PC, He C. M(6) a RNA methylation: from mechanisms to therapeutic potential. Embo J. 2021;40(3):e105977. doi: 10.15252/embj.2020105977
   PubMed Web of Science ®Google Scholar
• He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176. doi: 10.1186/s12943-019-1109-9
   PubMed Web of Science ®Google Scholar
• Liu T, Wei Q, Jin J, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020;48(7):3816–3831. doi: 10.1093/nar/gkaa048
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang S, He C, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer. 2020;19(1):46. doi: 10.1186/s12943-020-1146-4
   PubMed Web of Science ®Google Scholar
• Chen Y, Peng C, Chen J, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer. 2019;18(1):127. doi: 10.1186/s12943-019-1053-8
   PubMed Web of Science ®Google Scholar
• Ruan DY, Li T, Wang Y-N, et al. FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis. Oncogene. 2021;40(33):5168–5181. doi: 10.1038/s41388-021-01916-0
   PubMed Web of Science ®Google Scholar
• Xu Y, Ye S, Zhang N, et al. The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer. Cancer Commun (Lond). 2020;40(10):484–500. doi: 10.1002/cac2.12075
   PubMed Web of Science ®Google Scholar
• Huang J, Sun W, Wang Z, et al. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner. J Exp Clin Cancer Res. 2022;41(1):42. doi: 10.1186/s13046-022-02254-z
   PubMed Web of Science ®Google Scholar
• Su T, Wang Y-P, Wang X-N, et al. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of brevilin a. Life Sci. 2020;241:117169. doi: 10.1016/j.lfs.2019.117169
   PubMed Web of Science ®Google Scholar
• Jin Y, Kim YH, Park JY, et al. Methyllucidone inhibits STAT3 activity by regulating the expression of the protein tyrosine phosphatase MEG2 in DU145 prostate carcinoma cells. Bioorg Med Chem Lett. 2018;28(5):853–857. doi: 10.1016/j.bmcl.2018.02.012
   PubMed Web of Science ®Google Scholar
• Zou S, Tong Q, Liu B, et al. Targeting STAT3 in Cancer Immunotherapy. Mol Cancer. 2020;19(1):145. doi: 10.1186/s12943-020-01258-7
   PubMed Web of Science ®Google Scholar
• Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–120. doi: 10.1038/nature12730
   PubMed Web of Science ®Google Scholar
• Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharmacother. 2019;112:108613. doi: 10.1016/j.biopha.2019.108613
   PubMed Web of Science ®Google Scholar
• Chen X, Hua W, Huang X, et al. Regulatory role of RNA n(6)-methyladenosine modification in bone biology and osteoporosis. Front Endocrinol. 2019;10:911. doi: 10.3389/fendo.2019.00911
   PubMed Web of Science ®Google Scholar
• Sun D, Yang H, Fan L, et al. M6a regulator-mediated RNA methylation modification patterns and immune microenvironment infiltration characterization in severe asthma. J Cell Mol Med. 2021;25(21):10236–10247. doi: 10.1111/jcmm.16961
   PubMed Web of Science ®Google Scholar
• Wang J, Wang K, Liu W, et al. M6a mRNA methylation regulates the development of gestational diabetes mellitus in Han Chinese women. Genomics. 2021;113(3):1048–1056. doi: 10.1016/j.ygeno.2021.02.016
   PubMed Web of Science ®Google Scholar
• Chen J, Du B. Novel positioning from obesity to cancer: FTO, an m(6)A RNA demethylase, regulates tumour progression. J Cancer Res Clin Oncol. 2019;145(1):19–29. doi: 10.1007/s00432-018-2796-0
   PubMed Web of Science ®Google Scholar
• Relier S, Ripoll J, Guillorit H, et al. FTO-mediated cytoplasmic m(6)Am demethylation adjusts stem-like properties in colorectal cancer cell. Nat Commun. 2021;12(1):1716. doi: 10.1038/s41467-021-21758-4
   PubMed Web of Science ®Google Scholar
• Huang H, Wang Y, Kandpal M, et al. FTO-Dependent N 6 -methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking camp signaling. Cancer Res. 2020;80(16):3200–3214. doi: 10.1158/0008-5472.CAN-19-4044
   PubMed Web of Science ®Google Scholar
• Zhou G, Yan K, Liu J, et al. FTO promotes tumour proliferation in bladder cancer via the FTO/miR-576/CDK6 axis in an m6A-dependent manner. Cell Death Discov. 2021;7(1):329. doi: 10.1038/s41420-021-00724-5
   PubMed Web of Science ®Google Scholar
• Yang S, Wei J, Cui Y-H, et al. M(6)a mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019;10(1):2782. doi: 10.1038/s41467-019-10669-0
   PubMed Web of Science ®Google Scholar
• Wang C, Li L, Li M, et al. FTO promotes Bortezomib resistance via m6A-dependent destabilization of SOD2 expression in multiple myeloma. Cancer Gene Ther. 2023;30(4):622–628. doi: 10.1038/s41417-022-00429-6
   Google Scholar
• Tao L, Mu X, Chen H, et al. FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Clin Transl Med. 2021;11(2):e310. doi: 10.1002/ctm2.310
   PubMed Web of Science ®Google Scholar
• Zhang X, Sai B, Wang F, et al. Hypoxic BMSC-derived exosomal miRnas promote metastasis of lung cancer cells via STAT3-induced EMT. Mol Cancer. 2019;18(1):40. doi: 10.1186/s12943-019-0959-5
   PubMed Web of Science ®Google Scholar
• Wang B, Liu T, Wu J-C, et al. STAT3 aggravates TGF-β1-induced hepatic epithelial-to-mesenchymal transition and migration. Biomed Pharmacother. 2018;98:214–221. doi: 10.1016/j.biopha.2017.12.035
   PubMed Web of Science ®Google Scholar
• Li YL, Wu L-W, Zeng L-H, et al. ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3. Oncogene. 2020;39(39):6203–6217. doi: 10.1038/s41388-020-01428-3
   PubMed Web of Science ®Google Scholar
• Narimatsu M, Maeda H, Itoh S, et al. Tissue-specific autoregulation of the stat3 gene and its role in interleukin-6-induced survival signals in T cells. Mol Cell Biol. 2001;21(19):6615–6625. doi: 10.1128/MCB.21.19.6615-6625.2001
   PubMed Web of Science ®Google Scholar
• Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 inoncogenesis and transcriptional regulation. Cancer Res. 2005;65(3):939–947. doi: 10.1158/0008-5472.939.65.3
   PubMed Web of Science ®Google Scholar
• Lee H, Jeong AJ, Ye SK. Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep. 2019;52(7):415–423. doi: 10.5483/BMBRep.2019.52.7.152
   PubMed Web of Science ®Google Scholar
• Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–746. doi: 10.1038/nrc3818
   PubMed Web of Science ®Google Scholar
• Wong ALA, Hirpara JL, Pervaiz S, et al. Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin Investig Drugs. 2017;26(8):883–887. doi: 10.1080/13543784.2017.1351941
   PubMed Web of Science ®Google Scholar